MedTrace Logo

Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients

NCT01232062 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2015-07-23

No results posted yet for this study

Summary

To access the effectiveness of High-dose Cyclophosphamide Combined Chemotherapy combined with adoptive cellular therapy with dentritic and cytokine-induced killer cells in triple negative metastatic breast cancer patients

Conditions

  • Breast Neoplasms
  • Neoplasm Metastasis

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • JING YU, MD, PhD · Peking University Cancer Hospital & Institute

  • CHAO YING WANG, MD, PhD · Peking University Cancer Hospital & Institute

  • JUN REN, MD, PhD · Peking University Cancer Hospital & Institute

  • YU LIN ZHU, MD, PhD · Bei jing Cancer Hospital

  • Jie Zhang, MD. · Peking University Cancer Hospital & Institute

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-05-31
Completion
2013-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01232062 on ClinicalTrials.gov